Literature DB >> 21307580

Long-term cultured human skin mast cells are suitable for pharmacological studies of anti-allergic drugs due to high responsiveness to FcεRI cross-linking.

Sven Guhl1, Metin Artuc, Angelos Neou, Magda Babina, Torsten Zuberbier.   

Abstract

Human skin mast cells proliferated in the presence of interleukin (IL)-4+SCF (expanding 18-fold in 8 weeks) and acquired profound responsiveness towards high affinity IgE receptor (FcεRI) cross-linking, liberating about 75% of their histamine. In a proof-of-concept, we found that these cells are useful for pharmacological testing. Even a subtle inhibition of degranulation can be visualized. This model might prove valuable in tests of novel anti-allergic drugs.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21307580     DOI: 10.1271/bbb.100745

Source DB:  PubMed          Journal:  Biosci Biotechnol Biochem        ISSN: 0916-8451            Impact factor:   2.043


  12 in total

1.  Redefinition of the human mast cell transcriptome by deep-CAGE sequencing.

Authors:  Efthymios Motakis; Sven Guhl; Yuri Ishizu; Masayoshi Itoh; Hideya Kawaji; Michiel de Hoon; Timo Lassmann; Piero Carninci; Yoshihide Hayashizaki; Torsten Zuberbier; Alistair R R Forrest; Magda Babina
Journal:  Blood       Date:  2014-03-26       Impact factor: 22.113

2.  Humanized mouse model of mast cell-mediated passive cutaneous anaphylaxis and passive systemic anaphylaxis.

Authors:  Paul J Bryce; Rustom Falahati; Laurie L Kenney; John Leung; Christopher Bebbington; Nenad Tomasevic; Rebecca A Krier; Chia-Lin Hsu; Leonard D Shultz; Dale L Greiner; Michael A Brehm
Journal:  J Allergy Clin Immunol       Date:  2016-04-06       Impact factor: 10.793

3.  In vivo non-invasive staining-free visualization of dermal mast cells in healthy, allergy and mastocytosis humans using two-photon fluorescence lifetime imaging.

Authors:  Marius Kröger; Jörg Scheffel; Viktor V Nikolaev; Evgeny A Shirshin; Frank Siebenhaar; Johannes Schleusener; Jürgen Lademann; Marcus Maurer; Maxim E Darvin
Journal:  Sci Rep       Date:  2020-09-10       Impact factor: 4.379

Review 4.  Epigenetic and transcriptional control of mast cell responses.

Authors:  Silvia Monticelli; Cristina Leoni
Journal:  F1000Res       Date:  2017-11-29

5.  Apoptotic resistance of human skin mast cells is mediated by Mcl-1.

Authors:  Tarek Hazzan; Jürgen Eberle; Margitta Worm; Magda Babina
Journal:  Cell Death Discov       Date:  2017-08-21

6.  Retinoic Acid Negatively Impacts Proliferation and MCTC Specific Attributes of Human Skin Derived Mast Cells, but Reinforces Allergic Stimulability.

Authors:  Magda Babina; Metin Artuc; Sven Guhl; Torsten Zuberbier
Journal:  Int J Mol Sci       Date:  2017-02-28       Impact factor: 5.923

7.  IL-33 and MRGPRX2-Triggered Activation of Human Skin Mast Cells-Elimination of Receptor Expression on Chronic Exposure, but Reinforced Degranulation on Acute Priming.

Authors:  Zhao Wang; Sven Guhl; Kristin Franke; Metin Artuc; Torsten Zuberbier; Magda Babina
Journal:  Cells       Date:  2019-04-11       Impact factor: 6.600

8.  MRGPRX2 Is the Codeine Receptor of Human Skin Mast Cells: Desensitization through β-Arrestin and Lack of Correlation with the FcεRI Pathway.

Authors:  Magda Babina; Zhao Wang; Saptarshi Roy; Sven Guhl; Kristin Franke; Metin Artuc; Hydar Ali; Torsten Zuberbier
Journal:  J Invest Dermatol       Date:  2020-10-13       Impact factor: 8.551

9.  Dermal Extracellular Matrix-Derived Hydrogels as an In Vitro Substrate to Study Mast Cell Maturation.

Authors:  Emily W Ozpinar; Ariana L Frey; Greer K Arthur; Camilo Mora-Navarro; Andreea Biehl; Douglas B Snider; Glenn Cruse; Donald O Freytes
Journal:  Tissue Eng Part A       Date:  2020-11-19       Impact factor: 4.080

10.  Thymic Stromal Lymphopoietin Interferes with the Apoptosis of Human Skin Mast Cells by a Dual Strategy Involving STAT5/Mcl-1 and JNK/Bcl-xL.

Authors:  Tarek Hazzan; Jürgen Eberle; Margitta Worm; Magda Babina
Journal:  Cells       Date:  2019-08-05       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.